Tag: recovery

TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) reported the Corporation’s 2025 second quarter results and increases dividend. Iqbal Khan, Chief Financial Officer, commented:

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable’s May 2025 public offering, resulting from allegations that Sable may have issued materially misleading business information to the investing public.

Breathable joint support solutions address swelling, fatigue, and pain relief for travelers, athletes, and frontline workers this season

Muscle Building Supplements: A Game-Changer in Strength Training Programs

SURREY, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical minerals refining and lithium ion battery upcycling company, today announced that it, together with Lucid (NASDAQ: LCID) and other industry leaders has become a founding member of the Minerals for National Automotive Competitiveness Collaboration (MINAC), a partnership focused on accelerating the development and procurement of American-sourced critical mineral resources for use in automotive manufacturing by domestic automakers and Tier 1 suppliers. The other MINAC members are Alaska Energy Metals, Graphite One and Electric Metals.

Exploring Digital Asset Strategies to Inform Future Capital Innovation

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.